1.章友康，劉剛.腎病綜合征//諶貽璞.腎內科學.北京：人民衛生出版社，2008：1-12.

2. Zhou FD，Zhao MH，Zou WZ，et al.The changing spectrum of primary glomerular diseases within 15 years：A survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant，2009，24：870-876.

3. Zhou FD，Shen HY，Chen M，et al.The renal histopathological spectrum of patients with nephritic syndrome：an analysis of 1523 patients in a single Chinese centre.Nephrol Dial Transplant，2011，26：3993-3997.

4.蘇濤，劉曉玲，張宜苗，等.汞中毒相關性腎小球病的臨床病理分析.中華腎臟病雜志，2011，27：333-336.

5. Li SJ，Zhang SH，Chen HP，et al.Mercury-induced membranous nephropathy：clinical and pathological features. Clin J Am Soc Nephrol，2010，5：439-444.

6. Qu Z，Liu G，Li J，et al.Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy.Nephrol Dial Transplant，2012，27：1931-1937.

7. Kuroki A，Shibata T，Honda H，et al.glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis，membranous lupus nephritis，and idiopathic membranous nephropathy.Intern Med，2002，41：936-942.

8. Beck LH Jr，Bonegio RG，Lambeau G，et al.M-type phopholipase A2 receptor as target antigen in idiopathic membranous nephropathy.N Engl J Med，2009，361：11-21.

9. Debiec H，Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.N Engl J Med，2011，364：689-690.

10. Hofstra JM，Beck LH Jr，Beck DM，et al.Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol，2011，6：1286-1291.

11. Wei C，El Hindi S，Li J，et al.Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med，2011，17：952-960.

12. Huang J，Liu G，Zhang YM，et al.Plasma soluble rokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int，2013，84：366-372.

13.周福德，王海燕.難治性腎病綜合征.繼續醫學教育，2006，20：16-20.

14.孫頌山.免疫抑制藥//金有豫.藥理學.第5版.北京：人民衛生出版社，2001：402-407.

15. Li J，Zhang YM，Qu Z，et al.Low-dose cyclosporine treatment in Chinese nephrotic patients with idiopathic membranous nephropathy：An uncontrolled study with prospective follow-up.Am J Med Sci，2010，339：532-536.

16.環孢素A在腎內科的應用專家協作組.環孢素A治療腎小球疾病的應用共識.中華腎臟病雜志，2005，21：556-557.

17.嗎替麥考酚酯在腎內科應用專家共識組（趙明輝，陸福明整理）.嗎替麥考酚酯在腎內科應用專家共識.中華內科雜志，2006，45：965-966.

18. Liu WX，Li DM，Xu GS，et al.Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. Int J Clin Pharmcol Ther，2010，48：509-513.

19. Zhou J，Zhang Y，Liu G，et al.Efficacy and safety of leflunomide in treatment of steroid-dependent and steroidresistant adult onset minimal change disease.Clin Nephrol 2013，80：121-129.

20. Zhang WX，Zhou W，Zhang ZQ，et al.Interstitial lung diseases after leflunomide use in nephropathy：an analysis of reported cases in Chinese literature.Nephrol Dial Transplant，2011，26：1416-1420.

21.諶貽璞，主編.腎臟內科診療常規.北京：中國醫藥科技出版社，2013：1-19.

22. Kidney Disease：Improving Global Outcomes（KDIGO）Glomerulonephritis Work Group.KDIGO Clinical Practice Guidline for Glomerulonephritis.Kidney Int，2012，Suppl 2：139-274.

23. Chen M，Zhou FD，Zhao MH，et al.Normoalbumineaemia is associated with IgA nephropathy in primary glomerulopathy with nephrotic-range proteinuria in Chinese patients.Nephrol Dial Transplant，2011，26：1247-1252.

24. Busch M，Rüster C，Schink?the C，et al.Rituximab for the second-and thirdline therapy of idiopathic membranous nephropathy：a prosective single center study using a new treatment strategy.Clin Nephrol，2013，80：105-113.

25. Beck LH Jr，Fervenza FC，Beck DM，et al.Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.J Am Soc Nephrol 2011，22：1543-1550.

26. Hingorani SR，Weiss NS，Watkins SL.Predictors of peritonitis in children with nephrotic syndrome.Pediatr Nephrol，2002，17：678-682.

27. Stellato T，Cappelleri A，Farina M，et al.Severe reversible acute renal failure in idiopathic nephrotic syndrome. J Nephrol，2010，23：717-724.

28. Basford AW，Lewis J，Dwyer JP，et al.Membranous nephropathy with crescents.J Am Soc Nephrol，2011，22：1804-1808.

29. Barbour SJ，Greenwald A，Djurdjev Q，et al.Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis.Kidney Int，2012，81：190-195.

30. Kearon C，Akl EA，Comerota AJ，et al. Antithrombotic therapy for VTE disease：Antithrombotic Therapy and Prevention of Thrombosis，9th ed：American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest，2012，141：e419S-494S.

31. Wang C，Zhai Z，Yang Y，et al.Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism：a randomized，multicenter，controlled trial. Chest，2010，137：254-262.

32. Radhakrishnan J，Appel AS，Valeri A，et al.The nephrotic syndrome，lipids，and risk factors for cardiovascular disease.Am J Kidney Dis，1993，22：135-142.